Cargando…

Real World Experience of Second-Line Treatment Strategies after Palbociclib and Letrozole: Overall Survival in Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer

SIMPLE SUMMARY: Second-line treatment strategy after the first-line CDK4/6 inhibitor with aromatase inhibitor is considered by the behavior of hormone receptor positive human epidermal growth factor receptor-2 negative (HR+HER2−) metastatic breast cancer (MBC). Progression free survival 2 was one of...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Ji-Yeon, Shin, Junghoon, Ahn, Jin Seok, Park, Yeon Hee, Im, Young-Hyuck
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341332/
https://www.ncbi.nlm.nih.gov/pubmed/37444541
http://dx.doi.org/10.3390/cancers15133431
_version_ 1785072237206831104
author Kim, Ji-Yeon
Shin, Junghoon
Ahn, Jin Seok
Park, Yeon Hee
Im, Young-Hyuck
author_facet Kim, Ji-Yeon
Shin, Junghoon
Ahn, Jin Seok
Park, Yeon Hee
Im, Young-Hyuck
author_sort Kim, Ji-Yeon
collection PubMed
description SIMPLE SUMMARY: Second-line treatment strategy after the first-line CDK4/6 inhibitor with aromatase inhibitor is considered by the behavior of hormone receptor positive human epidermal growth factor receptor-2 negative (HR+HER2−) metastatic breast cancer (MBC). Progression free survival 2 was one of the association factors for overall survival of HR+HER2− MBC. Therefore, the second-line treatment strategy was important to improve prognosis in patients with HR+/HER2− MBC. ABSTRACT: Background: We analyzed real-world practice of second-line treatment in hormone receptor (HR)+ human epidermal growth factor receptor-2 (HER2)− metastatic breast cancer (MBC) following the first-line CDK4/6 inhibitor with letrozole. In addition, we evaluated the relationship between second-line treatment strategies and survival outcome. Methods: Using the clinical data warehouse, clinical information including MBC diagnosis, treatment and survival outcomes were collected. Results: In total, 305 patients were treated with the first-line palbociclib plus letrozole, and we evaluated 166 patients who were treated with second-line treatment. Of the 166 patients, 28.5% were treated with capecitabine (C), followed by exemestane with everolimus (EE) (27.3%) or cytotoxic chemotherapy other than capecitabine (T) (18.8%) and fulvestrant-based treatment or endocrine monotherapy (F) (12.7%). Eighteen patients (10.9%) were enrolled in clinical trials (CT). With regard to treatment strategies, and the median progression-free survival of second-line treatment in a metastatic setting (PFS2) was 7.4 months with C, 5.2 months with EE, 4.8 months with T, 3.6 months with F, and 3.6 months with CT (p = 0.066). In patients with visceral organ disease progression, C (31.3%) or T(31.3%) was the most common second-line treatment followed by EE (21.9%). Most of the 47 patients with bone metastasis alone were treated with EE (38.2%), followed by C (23.4%) and F (21.3%) (p = 0.008). The median overall survival of second-line treatment in a metastatic setting (OS2) was 42.3 months with C, 35.7 months with F, 30.7 months with EE, and 23.1 months with T. The median OS2 for those in CT was not reached (p = 0.064). ER driven BC, disease progression site and PFS2 were associated with OS and OS2 in HR+HER2− MBC (ps < 0.05). Conclusions: We suggested the second line treatment strategy was important to improve prognosis in patients with HR+/HER2− MBC, especially given the recent standardization of first-line treatment and the many available second-line options.
format Online
Article
Text
id pubmed-10341332
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103413322023-07-14 Real World Experience of Second-Line Treatment Strategies after Palbociclib and Letrozole: Overall Survival in Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Kim, Ji-Yeon Shin, Junghoon Ahn, Jin Seok Park, Yeon Hee Im, Young-Hyuck Cancers (Basel) Article SIMPLE SUMMARY: Second-line treatment strategy after the first-line CDK4/6 inhibitor with aromatase inhibitor is considered by the behavior of hormone receptor positive human epidermal growth factor receptor-2 negative (HR+HER2−) metastatic breast cancer (MBC). Progression free survival 2 was one of the association factors for overall survival of HR+HER2− MBC. Therefore, the second-line treatment strategy was important to improve prognosis in patients with HR+/HER2− MBC. ABSTRACT: Background: We analyzed real-world practice of second-line treatment in hormone receptor (HR)+ human epidermal growth factor receptor-2 (HER2)− metastatic breast cancer (MBC) following the first-line CDK4/6 inhibitor with letrozole. In addition, we evaluated the relationship between second-line treatment strategies and survival outcome. Methods: Using the clinical data warehouse, clinical information including MBC diagnosis, treatment and survival outcomes were collected. Results: In total, 305 patients were treated with the first-line palbociclib plus letrozole, and we evaluated 166 patients who were treated with second-line treatment. Of the 166 patients, 28.5% were treated with capecitabine (C), followed by exemestane with everolimus (EE) (27.3%) or cytotoxic chemotherapy other than capecitabine (T) (18.8%) and fulvestrant-based treatment or endocrine monotherapy (F) (12.7%). Eighteen patients (10.9%) were enrolled in clinical trials (CT). With regard to treatment strategies, and the median progression-free survival of second-line treatment in a metastatic setting (PFS2) was 7.4 months with C, 5.2 months with EE, 4.8 months with T, 3.6 months with F, and 3.6 months with CT (p = 0.066). In patients with visceral organ disease progression, C (31.3%) or T(31.3%) was the most common second-line treatment followed by EE (21.9%). Most of the 47 patients with bone metastasis alone were treated with EE (38.2%), followed by C (23.4%) and F (21.3%) (p = 0.008). The median overall survival of second-line treatment in a metastatic setting (OS2) was 42.3 months with C, 35.7 months with F, 30.7 months with EE, and 23.1 months with T. The median OS2 for those in CT was not reached (p = 0.064). ER driven BC, disease progression site and PFS2 were associated with OS and OS2 in HR+HER2− MBC (ps < 0.05). Conclusions: We suggested the second line treatment strategy was important to improve prognosis in patients with HR+/HER2− MBC, especially given the recent standardization of first-line treatment and the many available second-line options. MDPI 2023-06-30 /pmc/articles/PMC10341332/ /pubmed/37444541 http://dx.doi.org/10.3390/cancers15133431 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kim, Ji-Yeon
Shin, Junghoon
Ahn, Jin Seok
Park, Yeon Hee
Im, Young-Hyuck
Real World Experience of Second-Line Treatment Strategies after Palbociclib and Letrozole: Overall Survival in Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
title Real World Experience of Second-Line Treatment Strategies after Palbociclib and Letrozole: Overall Survival in Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
title_full Real World Experience of Second-Line Treatment Strategies after Palbociclib and Letrozole: Overall Survival in Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
title_fullStr Real World Experience of Second-Line Treatment Strategies after Palbociclib and Letrozole: Overall Survival in Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
title_full_unstemmed Real World Experience of Second-Line Treatment Strategies after Palbociclib and Letrozole: Overall Survival in Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
title_short Real World Experience of Second-Line Treatment Strategies after Palbociclib and Letrozole: Overall Survival in Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
title_sort real world experience of second-line treatment strategies after palbociclib and letrozole: overall survival in metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341332/
https://www.ncbi.nlm.nih.gov/pubmed/37444541
http://dx.doi.org/10.3390/cancers15133431
work_keys_str_mv AT kimjiyeon realworldexperienceofsecondlinetreatmentstrategiesafterpalbociclibandletrozoleoverallsurvivalinmetastatichormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativebreastcancer
AT shinjunghoon realworldexperienceofsecondlinetreatmentstrategiesafterpalbociclibandletrozoleoverallsurvivalinmetastatichormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativebreastcancer
AT ahnjinseok realworldexperienceofsecondlinetreatmentstrategiesafterpalbociclibandletrozoleoverallsurvivalinmetastatichormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativebreastcancer
AT parkyeonhee realworldexperienceofsecondlinetreatmentstrategiesafterpalbociclibandletrozoleoverallsurvivalinmetastatichormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativebreastcancer
AT imyounghyuck realworldexperienceofsecondlinetreatmentstrategiesafterpalbociclibandletrozoleoverallsurvivalinmetastatichormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativebreastcancer